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1. Introduction
Neuroblastoma is a cancer of the peripheral sympathetic nervous system, derived from
embryonic neural crest cells (a neuroendocrine tumor) and is one of the few cancers known to
undergo spontaneous regression from an undifferentiated state to a benign tumor.
Neuroblastoma is the most common extracranial solid tumor in children, accounting for 7%
to 8% of all childhood cancers. The prevalence is about 1 case per 7,000 live births. This
incidence is fairly uniform throughout the world, at least for industrialized nations. Neuro‐
blastoma is slightly more common in boys than in girls, with a male-to-female sex ratio of 1.1
to 1 in most large studies [1]. While it accounts for 7% of all childhood malignancies, neuro‐
blastoma accounts for 10% of childhood cancer mortality. Neuroblastoma is a pediatric
neoplasm that is the most common cancer diagnosed during infancy. POG and CCG institu‐
tions from 1986 to 2001 showed a median age at diagnosis of about 19 months. In this cohort,
36% were infants, 89% were younger than 5 years, and 98% were diagnosed by 10 years of age.
The distribution of cases by age shows that this is a disease of infancy and early childhood,
with the highest number of cases diagnosed in the first month of life [2].
2. Current outcome
Patients with low- and intermediate-risk NBL have an overall survival rate exceeding 90%
with a trend toward minimization of therapy [3,4,5]. Standard therapy for patients with high-
risk NBL involves multi-agent chemotherapy induction, surgery and external beam radio‐
therapy, myeloablative consolidation with autologous hematopoietic stem cell recue and
biologic agents, including the recent demonstration that GD2- directed immunotherapy
combined with cytokines significantly improves survival. Despite these achievements, 50% of
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patients with newly diagnosed high-risk disease, and less than 10% of patients whose disease
recurs, will survive [6].
3. General remarks
Neuroblastoma is very often called “enigmatic tumor” for its broad spectrum of clinical
presentation, biological features and prognosis varying from clinically incidence benign to
unresectable or metastic disease with very poor outcomes. Neuroblastomas can arise any‐
where throughout the sympathetic nervous system, most common primary site is adrenal
gland, followed by abdominal (extraadrenal), thoracic, cervical, and pelvic sympathetic
ganglia. Neuroblastoma metastasizes to lymph nodes, bone marrow, bones (long bones, flat
bone soft the scull, orbits), liver, and skin, rarely to lungs or brain. Widespread bone and bone
marrow disease causes bone pain, which can lead to limping, or irritability in a younger child.
There may be bone marrow replacement and symptoms such as anemia, bleeding, or infection.
Skin involvement is seen almost exclusively in infants with INSS stage Ms (4S) tumors and is
characterized by a variable number of nontender, bluish subcutaneous nodules.
Constitutional symptoms associated with disseminated disease may include failure to thrive
and fever, the latter observed most often in the presence of extensive bone metastases [7]
Regional lymph node metastases are noted in up to 35% of patients with apparently localized
tumors and 30% of patients with stage M (4) and Ms (4S) disease also have regional lymph
node involvement. Spread of tumor to lymph nodes outside the cavity of origin is considered
to be INSS stage 4 disease, but these patients may have a better outlook if there is no bone
marrow, cortical bone, or other parenchymal organ involvement. [8,9]
Most primary tumors occur within the abdomen (65%), although the frequency of adrenal
tumors is slightly higher in children (40%) compared with infants (25%). Infants also have more
thoracic and cervical primary tumors. A primary tumor cannot be found in about 1% of
patients.
4. Staging and stratification
The for decades used surgical-pathologic International Neuroblastoma Staging System (INSS)
– Table 1 [10] has been recently replaced by the International Neuroblastoma Risk Group
Staging System (INRGSS) [11]. The INRGSS uses radiologic features to distinguish locore‐
gional tumors (Table 2) that do not involve local structures (INRGS L1) from locally invasive
tumors (INRGS L2), exhibiting image defined risk factors (Table 3) [12]. Stages M and MS refer
to tumors that are widely metastatic or have an INSS 4 and 4s pattern of disease, respectively.
Neuroblastoma is classified into low-, intermediate-, or high-risk categories based upon
clinical and biological features, with risk category correlating with outcome. The recently
proposed INRG classification defines similar cohorts that will be used to assess clinical trial
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outcome. The International Neuroblastoma Response Criteria (INRC) provide a common basis
for disease response comparisons across clinical trials [13]. Importantly, the INRC has
limitations with respect to definitions of metastatic site response not measurable using
anatomical imaging (bone and bone marrow). A National Cancer Institute-sponsored inter‐
national meeting was held in 2012 to develop updated consensus response guidelines.
Response components of a revised INRC will includeprimary tumor dimensions using
anatomic imaging, and metastatic disease assessment using 123I-MIBG imaging and quanti‐
fication of bone marrow disease.
Stage 1: Localized tumor with complete gross excis ion, with or without microscopic residual disease;
representative ipsilateral lymph nodes negati ve for tumor microscopically (nodes attached and
removed with the primary tumor may be positive)
Stage 2A: Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph
nodes negative for tumor microscopically
Stage 2B: Localized tumor withor without komplete gross excision, with ipsilateral nonadherentlymph nodes
positive for tumor. Enlarged contralateral lymph nodes must benegative microscopically
Stage 3: Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node
involvement; or localized unilateral tumorwith contralateral regional lymphnode involvement; or
midline tumor with bilateral extensit by infiltration (unresectable) or by lymph node involvement
Stage 4: Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin,
and/or other organs (except as defined for stage 4S)
Stage 4S: Localized primary tumor (as defined for stage 1, 2A, or2B), with dissemin ation limited to skin, liver
and/or bone marrow (limited to infants <1 year of age)
Table 1. International Neuroblastoma Staging System
Ipsilateral tumor extension within two body compartments
Neck-chest, chest-abdomen, abdomen-pelvis
Neck
Tumor encasing carotid and/or vertebral artery and/or internal jugular vein
Tumor extending to base of skull
Tumor compressing the trachea
Cervico-thoracic junction
Tumor encasing brachial plexus roots
Tumor encasing subclavian vessels and/or vertebral and/or carotid artery
Tumor compressing the trachea
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Thorax
Tumor encasing the aorta and/or major branches
Tumor compressing the trachea and/or principal bronchi
Lower mediastinal tumor, infiltrating the costo-vertebral junction between T9 and T12
Thoraco-abdominal
Tumor encasing the aorta and/or vena cava
Abdomen/pelvis
Tumor infiltrating the porta hepatis and/or the hepatoduodenal ligament
Tumor encasing branches of the superior mesenteric artery at the mesenteric root
Tumor encasing the origin of the coeliac axis, and/or of the superior
mesenteric artery
Tumor invading one or both renal pedicles
Tumor encasing the aorta and/or vena cava
Tumor encasing the iliac vessels
Pelvic tumor crossing the sciatic notch
Intraspinal tumor extension whatever the location provided that:
More than one third of the spinal canal in the axial plane is invaded and/or the perimedullary
leptomeningeal spaces are not visible and/or the spinal cord signal is abnormal
Infiltration of adjacent organs/structures
Pericardium, diaphragm, kidney, liver, duodeno-pancreatic block, and mesentery
Conditions to be recorded, but not considered IDRFs
Multifocal primary tumors
Pleural effusion, with or without malignant cells
Ascites, with or without malignant cells
Table 2. Image-defined risk factors (IDRFs)
L1: Localized tumor not involving vital structures as defined by the list of image-defined risk factors and confined to one body
compartment
L2: Locoregional tumor with presence of one or more image-defined risk factors
M: Distant metastatic disease (expect stage MS)
MS: Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow
Table 3. International Neuroblastoma Risk Group Staging System
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5. Sporadic and familiar neuroblastoma
Most neuroblastomas occur sporadically; around 1-2% are familial and associated with
multiple primary tumours, usually occurring at <18 months of age. Familial disease has the
same diverse clinical behaviour as somatic neuroblastoma, ranging from aggressive progres‐
sion to spontaneous regression.11 Within the last 10 years significant advances have been in
the understanding of hereditary neuroblastoma, with germline mutations in two genes ALK
and paired homeobox 2b gene PHOX2B accounting for the majority of cases, which may
present in the neonatal period. ALK mutations are now known to be the most now known
common cause of hereditary neuroblastoma, and in familial neuroblastoma [14,15,16]
6. Associated conditions
Neuroblastoma can be associated with several inborn conditions, like Hirschsprung disease,
congenital central hypoventilation syndrome (CCHS or Ondine’s curse), neurofibromatosis
type I, or Beckwith-Wiedemann syndrome
7. Clinical presentation
The presenting signs and symptoms of neuroblastoma are highly variable with a broad
spectrum. Presenting symptoms of neuroblastoma depend on the location of the primary
tumor, presence of metastatic lesions, systemic symptoms from catecholamine secretion.
Weight loss and fever are present at advanced stages neuroblastoma.
8. Anatomical site of the primary tumour
8.1. Head and neck
Unilateral palpable mass developing in infants or in preschool age children, rarely are
diagnosed in newborn mimicking cervical teratoma. [17]
Horners syndrome (ptosis, miosis, anophthalmos, anhydrosis). This syndrome is unilateral,
Tatli reported a 28 old child with bilateral prosis [18]. Primary cervical neuroblastoma are
ussually non agressive and thein prognosis is very good. But some are fatal - extremely rare
case described Güzelmansur et al. – diagnosed prenatally with progression to brain. [19]
Orbit and eye exophthalmoses, periorbital ecchymoses (raccoon eyes), palpable masses, edema
of conjunctiva, papilledema, strabismus, anisocoria. The periorbital ecchymoses can be present
in about 20% of disseminated neuroblastoma. This clinical findings is related to obstruction of
the palpebral ond orbita vessels by metastatic lesions within orbital bones. Frequently these
Clinical Presentation of Neuroblastoma
http://dx.doi.org/10.5772/55921
7
children are investigated for an abuse or a trauma (basal skull fractures) [20,21]. Usually further
systemic symptoms are present – weight loss, fever.
Opsoclonus also known as dancing-eye syndrome, presents in early childhood with opsoclo‐
nus (rapid, multidirectional, conjugate eye movements) usually associated with myoclonus,
ataxia, and behavioral changes such as irritability and sleep problems.– opsoclonus-myoclonus
syndrome (OMS) [22]
Chest Upper thoracic tumours: Primary thoracic tumors present as symptomatic masses or
can be discovered incidentally when chest radiographs are obtained to evaluate patients
for  other  reasons.  High  thoracic  and  cervical  masses  can  be  associated  with  Horner
syndrome, which consists of unilateral ptosis, myosis, and anhydrosis. Occasionally, large
thoracic  tumors  are  associated with  mechanical  obstruction and resultant  superior  vena
cava syndrome.
Lower thoracic tumours: usually no symptoms, usually accidental discovery on chest X-ray or
thoracic CT performed for other reasons.
8.2. Abdominal neuroblastoma
About 60% of primary neuroblastomas arise in the abdomen, two thirds of them are from the
adrenal glands (adrenal neuroblastoma), one third are from paravertebral ganglion (extraa‐
drenal neuroblastoma). Only about one tenth of neuroblastoma are detected as an abdominal
mass during a routine examination. The mass is ussually fixed,and firm.
Symptoms: abdominal pain or fullness, abdominal mass, or rarely intestinal obstruction,
enlarged and/or displaced liver and spleen. Massive involvement of the liver with metastatic
disease is particularly frequent in infants with stage Ms (4S) and may result in respiratory
compromise (Pepper Syndrome). Occasionally, the size of primary or metastatic abdominal
tumors can result in compression of venous and lymphatic drainage from the lower extremi‐
ties, leading to scrotal and lower extremity edema. Rarely, patients will experience renin-
mediated hypertension because of compromise of renal vasculature.
Hypertension, tachycardia, flushing, and sweating are uncommon symptoms because
epinephrine is rarely released from most neuroblastomas, since they lack the enzyme necessary
for synthesis.
Only about one tenth of neuroblastoma are detected as an abdominal mass during a routine
examination. The mass is ussually fixed,and firm.
Spontaneous rupture from hemorrhage into the tumor occurs very rarely and only in rapidly
growing tumors.
There is a small subgroup of abdominal neuroblastomas arising near to the aortic bifurca‐
tion (commonly called organ of Zuckerkandl, O. Z.) to assess their biologic outcome and
problems in diagnosis and therapy. The organ of Zuckerkandl comprises of a small mass
of chromaffin cells derived from neural crest located along the aorta, beginning cranial to
the  superior  mesenteric  artery  or  renal  arteries  and extending to  the  level  of  the  aortic
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bifurcation or just beyond. When neuroblastoma arises these small  organs, normally not
visible  on  radiographs,  then  it  could  cause  compression  of  bowel  or  urine  bladder
(constipation, enuresis) [23].
Paraspinal tumors in the thoracic, abdominal, and pelvic regions are able to invade the spinal
canal through the neural foramina ( dumbbell tumor) causing spinal cord compression and
cause symptoms related to compression of nerve roots and spinal cord. The range of sympto‐
matology includes subacute or acute paraplegia, bladder or bowel dysfunction, or less
commonly radicular pain.
9. Paraneoplastic syndrome
Up to 2% of patients present with opsoclonus and myoclonus (OMS) (myoclonic jerking and
random eye movements). Often have localized disease and a good long-term prognosis.
Opsoclonus and myoclonus syndrome is manifested by rapid and chaotic eye movements,
ataxia, and myoclonia. Most children with this syndrome have a favorable outcome with
respect to their tumor, as this syndrome is correlated with an immune-mediated antitumor
host response [24].
Autonomous tumor secretion of vasoactive intestinal peptide (VIP) is another paraneoplastic
syndrome (Kerner-Morrison Syndrome) that is rarely associated with neuroblastoma. VIP
secretion can cause abdominal distension and intractable secretory diarrhea with associated
hypokalemia ; these symptoms usually resolve after removal of the tumor. chronic watery
diarrhea preceded the diagnosis of the tumor; these patients were considered to have ‘‘Primary
VIP secreting NTs.’’
10. Metastatic disease
NBL is associated with lymphatic and hematogenous metastatic disease.
Regional lymph node metastases are noted in 35% of patients with apparently localized
tumors.
The most common sites for hematogenous spread are: bones (skull, long bones, ribs, verte‐
bras),bone marrow, liver, skin and rarely brain or lungs.
Signs and symptoms of metastatic neuroblastoma include:
Pain  and  limping,  sphenoid  bone  and  retrobulbar  tissue  involvement  causes  orbital
ecchymoses swelling and proptosis  (raccoon face),  infants present as irritable and fussy.
Bone marrow involvement may result in pancytopenia. Respiratory distress may occur in
young babies with Stage IVS (Ms) disease -  due to enlarged liver.  Skin or subcutaneous
nodules are seen almost only in infants. These nodules are non-tender, bluish and mobile
- called the “blueberry muffin sign”.
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